Alliancebernstein L.P. Raises Stock Holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Alliancebernstein L.P. raised its position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 16.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 821,264 shares of the company's stock after acquiring an additional 113,261 shares during the period. Alliancebernstein L.P. owned approximately 1.51% of Bicara Therapeutics worth $14,306,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Norges Bank bought a new position in Bicara Therapeutics during the fourth quarter valued at $1,219,000. JPMorgan Chase & Co. raised its position in Bicara Therapeutics by 8,768.5% during the fourth quarter. JPMorgan Chase & Co. now owns 64,740 shares of the company's stock valued at $1,128,000 after purchasing an additional 64,010 shares during the period. Corebridge Financial Inc. bought a new position in shares of Bicara Therapeutics during the 4th quarter valued at approximately $167,000. Vanguard Group Inc. lifted its position in Bicara Therapeutics by 1,457.9% in the fourth quarter. Vanguard Group Inc. now owns 1,090,528 shares of the company's stock worth $18,997,000 after buying an additional 1,020,528 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Bicara Therapeutics in the 4th quarter worth about $647,000.

Wall Street Analyst Weigh In

Several research analysts have issued reports on BCAX shares. HC Wainwright dropped their target price on Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a research report on Thursday, March 27th. Cantor Fitzgerald restated an "overweight" rating and issued a $13.01 price target on shares of Bicara Therapeutics in a report on Thursday, March 13th. Finally, Wedbush reiterated an "outperform" rating and set a $31.00 price objective on shares of Bicara Therapeutics in a report on Thursday, March 27th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Bicara Therapeutics has a consensus rating of "Buy" and an average target price of $36.50.

Remove Ads

Bicara Therapeutics Trading Up 0.8 %

Shares of NASDAQ BCAX traded up $0.08 during trading hours on Monday, hitting $10.85. 54,274 shares of the stock were exchanged, compared to its average volume of 468,188. The firm has a fifty day moving average price of $12.76 and a 200-day moving average price of $16.76. Bicara Therapeutics Inc. has a 12 month low of $8.91 and a 12 month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). As a group, sell-side analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.